Medtronic Q2 revenue rises 6.6% to $9.0 billion; raises FY26 guidance
Medtronic reported second quarter fiscal 2026 results for the period ended October 24, 2025, with revenue of $8.961 billion and GAAP diluted EPS of $1.07, both up year over year. The company also raised its fiscal 2026 organic revenue growth and adjusted EPS guidance, which matters to shareholders because it signals higher expected earnings for the full year.
Key points
- Revenue of $8.961 billion rose 6.6% as reported and 5.5% organic; Cardiac Ablation Solutions revenue increased 71%.
- GAAP diluted EPS was $1.07, up 8%; non-GAAP diluted EPS was $1.36, also up 8%.
- FY26 organic revenue growth guidance raised to approximately 5.5% from approximately 5.0%.
- FY26 diluted non-GAAP EPS guidance set at $5.62 to $5.66, versus the prior $5.60 to $5.66, including a potential tariff impact of approximately $185 million.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 18, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.